Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
Clene (NASDAQ: CLNN) announced that President and CEO Rob Etherington will join a virtual panel on ALS treatments, hosted by Maxim Group on June 28 at 11 a.m. EDT. The discussion will address the urgent need for new therapies for amyotrophic lateral sclerosis (ALS), as current options are limited. Clene's lead candidate, CNM-Au8®, is in late-stage trials, with topline data expected in Q3 from a Phase 2/3 study. This drug aims to restore neuronal health with gold nanocrystals, enhancing energy production and offering neuroprotection.
- None.
- None.
SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Rob Etherington, the Company’s President and CEO, has been invited to participate in the “Innovations in ALS - Exploring New Treatments In Development” virtual panel presented by Maxim Group LLC and hosted by M-Vest at 11 a.m. EDT on Tuesday, June 28. M-Vest members can follow the live event live here. At the same link, non-members can sign up.
Amyotrophic lateral sclerosis (ALS) remains a highly debilitating and deadly neurological disease despite having approved therapies on the market. Current therapies provide benefits for some patients, but there remains a high unmet need for new therapies and research into the disease. The panel discussion, which will focus on current research and development in the field of ALS, will be moderated by Maxim Group Senior Biotech Analyst, Naz Rahman, CFA, and will feature Mr. Etherington along with Alon Ben-Noon, Co-Founder and CEO of NeuroSense Therapeutics.
Focused on advancing new medicines, Clene is currently in late-stage clinical development with its lead drug candidate, CNM-Au8®, as a potential treatment for ALS. The Company expects topline data in the third quarter from the registrational Phase 2/3 HEALEY ALS Platform trial that is evaluating CNM-Au8 in ALS patients. CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically-active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our substantial dependence on the successful commercialization of our drug candidates, if approved, in the future; our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies; our ability to achieve commercial success for our drug candidates, if approved; our ability to obtain additional funding for operations; the effects of inflation; the effects of staffing and materials shortages; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Investor Contact
Morgan Brown
Chief Financial Officer
morgan@clene.com
+1-801-201-9626
Media Contact
Erica Fiorini, Ph.D., or David Schull
Russo Partners, LLC
Erica.fiorini@russopartnersllc.com
David.schull@russopartnersllc.com
+1-212-845-4253
FAQ
What event is Clene scheduled to participate in on June 28, 2022?
What is CNM-Au8 and its significance for ALS?
When is Clene expecting topline data from the HEALEY ALS Platform trial?
Who is moderating the virtual panel on ALS hosted by Maxim Group?
What is the main goal of the upcoming panel discussion on ALS?
